NEW YORK, Sept. 28, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced
that the Company secured an equity interest in Tevva Motors
Ltd, an electric truck producer with range extended vehicles on the
road now.
Tevva Motors Ltd is a UK-based, leading developer of modular
electrification systems for medium duty commercial vehicles. Using
a system engineering approach, Tevva has developed world-class
electric vehicle technology that adheres to the most rigorous of
standards to ensure safety, reliability and durability. Tevva's
core proprietary technologies – comprising battery pack and
management system, control system, software, and optional range
extender – are applicable to almost any current 7.5t – 14t truck
and is supplied as a package to OEMs for integration with their
vehicles.
Anthony Hayes, CEO of AIkido,
noted, "From a commercial standpoint, delivery trucks are a
$100 billion global market and demand
for a cost effective, zero emission solution is growing by the day.
With strategic partners and early customers including, Ryder,
Hitachi and UPS, and with Tevva vehicles already being used in
their delivery services, Tevva is well positioned to take advantage
of this rapidly growing sector." Mr. Hayes went on to state,
this unique and high growth opportunity represents an opportunity
to partake in a rapidly expanding field, with the possibility of an
exit in early 2022 as Tevva pursues a public listing. As we
continue to focus on our core business, which is drug
development. However, in our search for opportunities in our
space, this unique growth opportunities with strong likelihood for
monetization events, was presented to us. We are always
looking to create shareholder value while limiting exposure in
exciting and growing industries. We hope this short-term
opportunity becomes an asset for our shareholders, like
DatChat."
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology Company with a diverse portfolio of small-molecule
anti-cancer therapeutics. The Company's platform consists of
patented technology from leading universities and researchers, and
we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world
renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse
pipeline of therapeutics includes therapies for pancreatic cancer
and prostate cancer. We are constantly seeking to grow our pipeline
to treat unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas,
Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aikido-pharma-secures-interest-in-electric-truck-maker-tevva-motors-ltd-301386841.html
SOURCE AIkido Pharma Inc.